company background image
ARDX logo

Ardelyx NasdaqGM:ARDX Voorraadrapport

Laatste prijs

US$6.09

Marktkapitalisatie

US$1.4b

7D

3.2%

1Y

52.3%

Bijgewerkt

04 Nov, 2024

Gegevens

Financiële gegevens bedrijf +

Ardelyx, Inc.

NasdaqGM:ARDX Voorraadrapport

Marktkapitalisatie: US$1.4b

ARDX Overzicht aandelen

Ardelyx, Inc., een biofarmaceutisch bedrijf, ontdekt, ontwikkelt en verkoopt geneesmiddelen voor de behandeling van gastro-intestinale en cardiovasculaire therapeutische gebieden in de Verenigde Staten en internationaal.

Ardelyx, Inc. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Ardelyx
Historische aandelenkoersen
Huidige aandelenkoersUS$6.09
52 Week HoogtepuntUS$10.13
52 Week LaagUS$3.43
Bèta0.89
11 maand verandering-10.70%
3 maanden verandering0.16%
1 Jaar Verandering52.25%
33 jaar verandering403.31%
5 jaar verandering1.16%
Verandering sinds IPO-56.84%

Recent nieuws en updates

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Nov 03
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Ardelyx, Inc.'s (NASDAQ:ARDX) Shares Lagging The Industry But So Is The Business

Oct 24
Ardelyx, Inc.'s (NASDAQ:ARDX) Shares Lagging The Industry But So Is The Business

Is Ardelyx (NASDAQ:ARDX) Weighed On By Its Debt Load?

Aug 25
Is Ardelyx (NASDAQ:ARDX) Weighed On By Its Debt Load?

Recent updates

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Nov 03
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Ardelyx, Inc.'s (NASDAQ:ARDX) Shares Lagging The Industry But So Is The Business

Oct 24
Ardelyx, Inc.'s (NASDAQ:ARDX) Shares Lagging The Industry But So Is The Business

Is Ardelyx (NASDAQ:ARDX) Weighed On By Its Debt Load?

Aug 25
Is Ardelyx (NASDAQ:ARDX) Weighed On By Its Debt Load?

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Aug 07
Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Ardelyx Faces Rising Challenges Despite Revenue Growth

Aug 05

Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 04
Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Ardelyx: Increased Focus On Ibsrela Due To Xphozah's Uncertain Outlook

Jul 13

Why Investors Shouldn't Be Surprised By Ardelyx, Inc.'s (NASDAQ:ARDX) 25% Share Price Plunge

Jul 05
Why Investors Shouldn't Be Surprised By Ardelyx, Inc.'s (NASDAQ:ARDX) 25% Share Price Plunge

Ardelyx: Strong Execution, Fairly Valued

May 10

Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

May 04
Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Ardelyx Stock: A Crowded Market Curbs The Enthusiasm (Rating Downgrade)

May 03

Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing

Apr 17
Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing

Ardelyx Shrugs Off 'Mixed' Q4 Earnings

Mar 13

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Feb 24
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance

Feb 20

Ardelyx's XPHOZAH Still An Afterthought To The Pros

Jan 31

Ardelyx: FDA Approval For Xphozah Grants Further Sales Enhancement

Jan 10

Ardelyx, Inc.'s (NASDAQ:ARDX) Business Is Yet to Catch Up With Its Share Price

Jan 04
Ardelyx, Inc.'s (NASDAQ:ARDX) Business Is Yet to Catch Up With Its Share Price

Despite Lacking Profits Ardelyx (NASDAQ:ARDX) Seems To Be On Top Of Its Debt

Dec 14
Despite Lacking Profits Ardelyx (NASDAQ:ARDX) Seems To Be On Top Of Its Debt

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Aug 03
Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt

Jul 31
Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt

Pinning Down Ardelyx, Inc.'s (NASDAQ:ARDX) P/S Is Difficult Right Now

Apr 17
Pinning Down Ardelyx, Inc.'s (NASDAQ:ARDX) P/S Is Difficult Right Now

Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Mar 30
Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Dec 14
Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

What To Expect For Ardelyx In The Coming Month

Oct 18

Ardelyx: Potential For Growth, But Must Strengthen Its Financial Position

Oct 04

Rendement voor aandeelhouders

ARDXUS BiotechsUS Markt
7D3.2%-0.7%-1.6%
1Y52.3%19.8%30.8%

Rendement versus industrie: ARDX exceeded the US Biotechs industry which returned 19.8% over the past year.

Rendement versus markt: ARDX exceeded the US Market which returned 30.8% over the past year.

Prijsvolatiliteit

Is ARDX's price volatile compared to industry and market?
ARDX volatility
ARDX Average Weekly Movement7.5%
Biotechs Industry Average Movement9.6%
Market Average Movement6.0%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

Stabiele aandelenkoers: ARDX has not had significant price volatility in the past 3 months compared to the US market.

Volatiliteit in de loop van de tijd: ARDX's weekly volatility (8%) has been stable over the past year.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
2007267Mike Raabwww.ardelyx.com

Ardelyx, Inc., een biofarmaceutisch bedrijf, ontdekt, ontwikkelt en verkoopt geneesmiddelen voor de behandeling van gastro-intestinale en cardiovasculaire therapeutische gebieden in de Verenigde Staten en daarbuiten. De belangrijkste productkandidaat van het bedrijf is tenapanor voor de behandeling van patiënten met prikkelbare darmsyndroom met constipatie. Het ontwikkelt ook XPHOZAH, dat zich in Fase III van het klinisch onderzoek bevindt om serumfosfor te verminderen bij volwassenen met chronische nierziekte (CKD) aan de dialyse, of hyperfosfatemie; RDX013, een kaliumsecretagoog, voor de behandeling van verhoogd serumkalium, of hyperkaliëmie, een probleem bij patiënten met nier- en/of hartfalen; en RDX020, voor volwassen patiënten met metabole acidose, een ernstige elektrolytenstoornis.

Ardelyx, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Ardelyx zich tot de beurswaarde?
ARDX fundamentele statistieken
MarktkapitalisatieUS$1.44b
Inkomsten(TTM)-US$72.58m
Inkomsten(TTM)US$251.85m

5.7x

P/S-verhouding

-19.9x

Koers/Winstverhouding

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ARDX resultatenrekening (TTM)
InkomstenUS$251.85m
Kosten van inkomstenUS$85.54m
BrutowinstUS$166.31m
Overige uitgavenUS$238.89m
Inkomsten-US$72.58m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)-0.31
Brutomarge66.03%
Nettowinstmarge-28.82%
Schuld/Eigen Vermogen Verhouding79.0%

Hoe presteerde ARDX op de lange termijn?

Bekijk historische prestaties en vergelijking